Remove Biopharma Remove Medical science Remove Prescription
article thumbnail

7 commercial, sales, and marketing predictions for 2023

pharmaphorum

With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance. Food and Drug Administration’s Office of Prescription Drug Promotion ( OPDP ).”.

article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

There is also a looming, time-sensitive reality that biopharma companies face once their products hit the market: they need to recoup the costs of development as quickly as possible before drug patents expire and generics threaten sales. sales, medical science liaisons, etc.).